Tülay Kılıçaslan Ayna

Tülay Kılıçaslan Ayna

Auto-generated profile, based on publicly available information

Tülay Kılıçaslan Ayna

Department of Medical Biology, Faculty of Medicine Izmir Katip Celebi University Izmir Turkiye

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2025 in The FASEB Journal
Verified
Journal Article
Open access
BABurcu Çerçi Alkaç
Burcu Çerçi Alkaç
MSMustafa Soyöz
Mustafa Soyöz
TATülay Kılıçaslan Ayna
Tülay Kılıçaslan Ayna
MPMelek Pehlivan
Melek Pehlivan
IPİbRahim Pirim
İbRahim Pirim
Neuroblastoma (NB), a common pediatric cancer, is often associated with poor prognosis due to resistance to conventional therapies. Abemaciclib, a selective inhibitor of CDK4/6, is known for its ability to block cell cycle progression and induce cell death in various cancer types. In this study, we explore its potential therapeutic impact on NB by assessing its effects on cell proliferation, apoptosis, and the regulation of microRNAs (miRNAs) that are related to NB progression. Antiproliferative effect of abemaciclib, doxorubicin, cisplatin, and temozolomide (TMZ) were detected by MTT method. Combinations of abemaciclib–doxorubicin, abemaciclib–cisplatin, and abemaciclib–TMZ were also investigated by applying IC50 doses of the drugs for 24 h. ELISA and flow cytometry were performed for apoptosis detection, and for cell cycle analysis, flow cytometry was used. The expression levels of eight apoptosis, threee tumor suppressors, two oncogenes, and nine cell cycle‐related genes were analyzed by quantitative PCR. Moreover, the expression levels of five NB‐related miRNAs were determined. IC50 doses of abemaciclib, doxorubicin, cisplatin, and TMZ were found to be 4.757, 1.958, 34.21, and 240.7 uM in the 24 h, respectively. The combination of the drugs increased apoptosis and decreased cell migration and colony formation rates. The highest expression level difference was observed in PUMA when control and dose groups were compared. Increased expression levels of hsa‐mir‐18a‐5p and hsa‐miR‐124‐3p were detected in all drug‐treated groups compared to the control group. Our results highlight the potential of abemaciclib as a promising treatment strategy for NB, particularly when used in combination with other therapies to overcome resistance and improve clinical outcomes.

3 January 2026 in Gene Reports
Verified
Journal Article
Closed access
BABurcu Çerçi Alkaç
Burcu Çerçi Alkaç
MSMustafa Soyöz
Mustafa Soyöz
TATülay Kılıçaslan Ayna
Tülay Kılıçaslan Ayna
MPMelek Pehlivan
Melek Pehlivan
IPİbRahim Pirim
İbRahim Pirim

10 August 2026 in Bioorganic Chemistry
Verified
Journal Article
Closed access
MPMelek Pehlivan
Melek Pehlivan
BÇBurcu Çerçi
Burcu Çerçi
MKMerve Karaman
Merve Karaman
SCSuleyman Selim Cinaroglu
Suleyman Selim Cinaroglu
TATülay Kılıçaslan Ayna
Tülay Kılıçaslan Ayna
HSHakkı Ogün Sercan
Hakkı Ogün Sercan

15 December 2020 in ARCHIVES OF CLINICAL AND EXPERIMENTAL MEDICINE
Verified
Journal Article
Open access
PDF file
MBMasallah Baran
Masallah Baran
YAYeliz Çağan Appak
Yeliz Çağan Appak
BABetül Aksoy
Betül Aksoy
ISİ̇̇smail Sert
İ̇̇smail Sert
OIOnur Işik
Onur Işik
CTCem Tuğmen
Cem Tuğmen
Microvillus inclusion disease is a cause of congenital intestinal intractable diarrhea. Total parenteral nutrition is required throughout life and the patients need intestinal transplantation for survival. The new Coronavirus Disease 2019 (COVID-19) caused a worldwide pandemic in January 2020. Emergency surgical interventions are suggested to carrying out by taking appropriate measures during the pandemic period. In this case report, we aimed to discuss the small bowel transplantation management during the COVID-19 pandemic by presenting a child with microvillus inclusion disease who was underwent emergency small bowel transplantation due to the appropriate cadaveric organ donation.